Yes, lurasidone is an atypical antipsychotic medication with established antipsychotic properties.
Lurasidone is FDA-approved as an atypical antipsychotic for treating bipolar I depression in adults and adolescents (10-17 years), functioning through dopamine D2 and serotonin 5-HT2A receptor antagonism 1.
Mechanism of Action
Lurasidone exerts its antipsychotic effects through multiple receptor interactions:
- High-affinity antagonism at dopamine D2 receptors (Ki = 1 nM) and serotonin 5-HT2A receptors (Ki = 0.5 nM) 1
- Additional activity at 5-HT7 receptors (Ki = 0.5 nM) and partial agonism at 5-HT1A receptors (Ki = 6.4 nM) 1
- Notably lacks significant affinity for histamine H1 and muscarinic M1 receptors (IC50 > 1,000 nM), which distinguishes it from many other antipsychotics 1
This receptor profile confirms lurasidone's classification as an atypical antipsychotic, with its clinical efficacy mediated through combined dopamine D2 and serotonin 5-HT2A receptor antagonism 1.
Clinical Evidence
Guideline recognition: Multiple clinical practice guidelines acknowledge lurasidone among atypical antipsychotic agents. The 2017 obesity pharmacotherapy guideline specifically identifies lurasidone and ziprasidone as the most weight-neutral antipsychotics in their class 2. The 2025 INTEGRATE schizophrenia guidelines include lurasidone within the broader category of antipsychotic treatment options 3.
Research support: Lurasidone demonstrates efficacy in treating acute schizophrenia and bipolar depression, improving psychiatric rating scales and reducing depressive symptoms 4. It shows comparable effectiveness to other atypical antipsychotics (with the possible exception of clozapine) while maintaining a favorable metabolic profile 5.
Distinguishing Characteristics
Compared to other antipsychotics, lurasidone presents:
- Lower metabolic burden: Minimal weight gain risk, with rates comparable to placebo 4, 6
- Reduced sedation: Due to lack of H1 receptor affinity 7
- Potential procognitive effects: Attributed to 5-HT7 antagonism 7
Common pitfall: Higher rates of akathisia and extrapyramidal symptoms occur compared to some other atypical antipsychotics, though these are generally manageable with dose adjustment 5, 6.
Dosing Considerations
Critical requirement: Lurasidone must be taken with food (at least 350 calories) to ensure adequate absorption 1. This is a non-negotiable administration requirement that substantially affects bioavailability 1.
The evidence unequivocally establishes lurasidone as a legitimate atypical antipsychotic with documented efficacy through dopamine and serotonin receptor antagonism, FDA approval for psychiatric indications, and inclusion in major treatment guidelines 1.